AccessibilityHelp
BioSyent logo

BioSyent(TSXV) RX

Market CapCA$191.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1988)+1,520%
5 Year+164%
1 Year+54%
1 Month-3%
CA$16.95
-0.70%
-0.12Today
BioSyent last closing stock price
MetricPriceDate
Last closeCAD 16.952026-10-22
BioSyent stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.81%CAD 16.022026-10-15
1 month-3.09%CAD 17.492026-09-22
3 month+15.4%CAD 14.692026-07-24
Year to date+34.63%CAD 12.592025-12-31
1 year+54.34%CAD 10.982025-10-22
3 year+129.87%CAD 7.372023-10-23
5 year+163.77%CAD 6.432021-10-21
Since inception+1,520.12%CAD 1.051988-09-12

BioSyent Financials at a Glance

Market Cap

CA$191.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$55.67M

Net Income (TTM)

CA$9.87M

EPS (TTM)

CA$0.86

P/E Ratio

19.44

Dividend

CA$0.22

Beta (Volatility)

0.03 (Low)

Price

CA$16.95

Volume

11,018

Open

CA$17.07

Previous Close

CA$16.95

Daily Range

CA$16.25 - CA$17.07

52-Week Range

CA$10.65 - CA$17.50

Estimated Earnings Date

Nov 19, 2026

RX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioSyent

BioSyent Inc. is a Canadian pharmaceutical company focused on acquiring, licensing, developing, and selling healthcare products both domestically and internationally. The company specializes in innovative solutions for various medical conditions, particularly in the areas of iron deficiency anemia and women's health.

Products and Services
  • FeraMAX products for iron deficiency anemia treatment and prevention
  • Tibella, a hormone replacement therapy for menopausal symptoms
  • Inofolic, addressing polycystic ovarian syndrome symptoms
Growth Outlook
  • Recent quarterly revenue increased to CAD 19.87 million, up from CAD 13.91 million
  • Net income for Q2 2026 reached CAD 2.85 million, reflecting strong profitability
  • Consistent demand for iron supplements and women's health products supports future growth
Financial Highlights
  • Trailing twelve-month revenue of CAD 66.5 million, showcasing robust sales performance
  • Net profit margin of 17.73%, indicating effective cost management
  • Strong cash flow with free cash flow per share of CAD 1.04
BioSyent Inc. has established itself as a key player in the pharmaceutical industry, particularly in niche markets such as iron deficiency and women's health. The company's diverse product portfolio, including FeraMAX and Tibella, addresses significant health concerns, positioning it well for continued growth. Recent financial performance highlights a strong upward trend in revenue and profitability, with a notable increase in net income in the latest quarter. The company's effective cost management strategies have resulted in a healthy net profit margin, further enhancing its financial stability. With a solid foundation and a focus on innovative healthcare solutions, BioSyent Inc. presents an intriguing opportunity for potential investors interested in the pharmaceutical sector.
AI Generated • Oct 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

61

CEO

René C. Goehrum

Website

www.biosyent.com

Headquarters

Mississauga, ON L5N 6M1, CA

RX Financials

Key Financial Metrics (TTM)

Gross Margin

70.21%

Operating Margin

23.21%

Net Income Margin

17.73%

Return on Equity

22.92%

Return on Capital

26.74%

Return on Assets

16.32%

Earnings Yield

5.14%

Dividend Yield

1.27%

Payout Ratio

24.01%

Stock Overview

Market Cap

CA$191.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.31M

Volume

11.02K

Avg. Volume

10.73K

Financials (TTM)

Gross Profit

CA$39.09M

Operating Income

CA$12.92M

EBITDA

CA$15.12M

Operating Cash Flow

CA$12.09M

Capital Expenditure

-CA$298.65K

Free Cash Flow

CA$11.80M

Cash & ST Invst.

CA$8.94M

Total Debt

CA$3.14M

BioSyent Performance Analysis

BioSyent annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 27,925,187-2.4%
20232023-12-31CAD 31,590,30213.1%
20242024-12-31CAD 35,030,89710.9%
20252025-12-31CAD 43,051,98322.9%
BioSyent sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3020.1%
Q42025-12-31-20.9%
Q12026-03-3143.8%
Q22026-06-3042.9%
BioSyent annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD 0.44-10.8%
20232023-12-31CAD 0.5322.0%
20242024-12-31CAD 0.6216.0%
20252025-12-31CAD 0.7827.2%
BioSyent sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3027.8%
Q42025-12-31-21.7%
Q12026-03-3111.1%
Q22026-06-3025.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$19.87M

+95.2%

Gross Profit

CA$12.92M

+63.3%

Gross Margin

65.02%

N/A

Market Cap

CA$191.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$3.19M

N/A

Employees

60

N/A

Net Income

CA$2.85M

+41.2%

EBITDA

CA$4.98M

+67.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$8.94M

-56.1%

Total Debt

CA$3.14M

+233.3%

Accounts Receivable

CA$6.77M

+37.5%

Inventory

CA$10.74M

+121.0%

Long Term Debt

CA$698.77K

-4.9%

Short Term Debt

CA$2.44M

+1079.2%

Return on Assets

16.32%

N/A

Return on Invested Capital

27.70%

N/A

Free Cash Flow

CA$2.54M

-26.0%

Operating Cash Flow

CA$2.55M

-26.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDP.TOMedexus Pharmaceuticals Inc.
CA$4.94-0.80%
EBM.VEastwood Bio-Medical Canada Inc.
CA$1.92+13.61%
CPH.TOCipher Pharmaceuticals Inc.
CA$13.65+2.55%
CSCI.TOCOSCIENS Biopharma Inc.
CA$8.62+0.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$82.11-20.47%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$53.45+20.68%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$10.19-14.66%
NOKNokia
$7.88-14.81%

Questions About RX

What is the current price of BioSyent?

BioSyent is trading at CA$16.95 per share.

What is the 52-week range for BioSyent?

Over the past 52 weeks, BioSyent has traded between CA$10.65 and CA$17.50.

How much debt does BioSyent have?

As of the most recent reporting period, BioSyent reported total debt of CA$3.14M.

How much cash does BioSyent have on hand?

BioSyent reported CA$5.18M in cash and cash equivalents in its most recent financial results.

What is BioSyent’s dividend yield?

BioSyent currently has a dividend yield of 1.27%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services